NOVOLOG (insulin aspart recombinant) – an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. The primary activity of insulin, including insulin aspart, is regulation of glucose metabolism. Insulin and its analogs blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the […]
ACTOS (pioglitazone) – a thiazolidinedione (TZD) and an agonist for peroxisome proliferator activated receptor (PPAR) gamma commonly used to treat type 2 diabetes mellitus. ACTOS decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. FDA approved uses: […]
LANTUS (insulin glargine recombinant) – a acting human insulin analog indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral […]
JANUVIA (sitagliptin) – a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. DPP-4 inhibitors, are believed to exert their actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. By increasing and prolonging active incretin levels, […]